InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,070.29
(
1.19%
)
US TECH 100
16,998.80
(
1.47%
)
Dow Jones
38,485.57
(
0.64%
)
Brent Oil
87.21
(
0.92%
)
Bitcoin
66,627.79
(
-0.34%
)
Post# of 30
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

FooBarAndGrill

Send PM Follow Ignore
Followers 44
Posts 3130
Boards Moderated 2
Alias Born 01/18/2016

FooBarAndGrill

Member Level

Re: None

Monday, 06/05/2017 1:27:42 PM

Monday, June 05, 2017 1:27:42 PM

Post# of 30
LOXO-195 was designed to address anticipated mechanisms of acquired resistance in cancers exposed to a prior TRK inhibitor, including “solvent front” mutations (e.g. NTRK1 G595R, NTRK3 G623R), which are not well-addressed by existing investigational agents. LOXO-195 will be developed as a sequential treatment, to follow larotrectinib or another TRK inhibitor, to extend the total time of benefit from TRK inhibition.

Arriba, Abajo, al Centro, y pa’dentro!

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up